NCI Launches Phase 2 Clinical Trial of Puma's Neratinib and Pfizer's Palbociclib for HER2-Positive Solid Tumors
Expanding HER2-Targeted Therapy Through the ComboMATCH Platform
This Phase 2 clinical trial (NCT06126276, EAY191-N5), led by the National Cancer Institute (NCI) and the ECOG-ACRIN Research Group, focuses on patients with HER2-positive solid tumors, excluding breast cancer. It compares the efficacy of neratinib (NERLYNX) monotherapy from Puma Biotechnology (PBYI) with the combination of palbociclib (IBRANCE) from Pfizer (PFE). This study is conducted as a sub-protocol of ComboMATCH, a platform clinical trial that matches patients with the optimal drug combination based on their individual genomic profiles, testing the feasibility of precision medicine. It represents an attempt to establish a new treatment standard for patients with HER2 protein overexpression in solid tumors other than breast cancer.
Overcoming Resistance Mechanisms Through Dual-Pathway Blockade
The core of this trial lies in the synergistic effect of simultaneously administering neratinib, a pan-ERBB tyrosine kinase inhibitor (TKI), and palbociclib, a CDK4/6 inhibitor. Neratinib blocks the HER2 signaling pathway on cancer cells, but cells can acquire resistance by activating alternative pathways. By combining it with palbociclib, which inhibits CDK4/6, a key switch in cell cycle progression, the study aims to simultaneously block both the upstream HER2 signal and the downstream effector CDK4/6, thereby more completely inhibiting tumor growth. A key objective of this research is to verify the impact of dual-pathway blockade compared to single-agent therapy on tumor growth inhibition and progression-free survival (PFS).
Expanding the HER2-Targeted Market to Non-Breast Solid Tumors
The global HER2-targeted anticancer drug market is currently valued at over $9 billion as of 2025 and is experiencing high annual growth. While the existing HER2-targeted market has been concentrated on breast cancer, it has recently expanded to include various non-breast solid tumors such as gastric cancer, colorectal cancer, and biliary tract cancer. In particular, Enhertu, developed by Daiichi Sankyo and AstraZeneca, received its first FDA approval in April 2024 as a tumor-agnostic treatment for HER2-positive metastatic solid tumors, significantly changing the market landscape. In this environment, the combination of neratinib and palbociclib is attracting attention as an alternative that can improve patient convenience compared to antibody-drug conjugates (ADCs), which are administered intravenously, as an oral targeted therapy combination.
Competitive Landscape Based on Regulatory History and Commercial Impact
Neratinib received its first FDA approval in July 2017 as an extended adjuvant therapy for early-stage HER2-positive breast cancer, and the Oncologic Drugs Advisory Committee (ODAC) recommended approval with a vote of 12 in favor and 4 against. In February 2020, its approval was expanded to include metastatic HER2-positive breast cancer in combination with capecitabine. Palbociclib, on the other hand, is a blockbuster drug from Pfizer that received accelerated approval in February 2015 as a treatment for ER+/HER2- metastatic breast cancer and full approval in March 2017. If this Phase 2 clinical trial demonstrates clinical significance in non-breast solid tumors, it could lead to the expansion of the approved indications for these two drugs beyond off-label use, maximizing the pipeline value of both companies.
This Phase 2 clinical trial represents a significant test for the global HER2-targeted anticancer drug market, currently valued at approximately $9 billion in 2025, to validate the efficacy of the first oral pan-HER TKI and CDK4/6 inhibitor combination therapy. In the short term, it can provide clinical evidence to immediately expand the indications of neratinib and palbociclib, which have already received FDA approval, to patients with non-breast solid tumors. In the medium to long term, it can offer an alternative treatment option with superior convenience and cost-effectiveness compared to expensive injectable ADC therapies in the HER2-positive tumor-agnostic treatment market, which has been pioneered by Daiichi Sankyo and AstraZeneca's Enhertu. From a researcher and clinician perspective, it will be an opportunity to demonstrate the pharmacological utility of combination therapy for overcoming alternative pathway activation and resistance that occurs after targeted therapy administration, through the precision medicine platform ComboMATCH. From an investor perspective, it will serve as a key indicator for evaluating the success of Puma Biotechnology's (PBYI) market diversification of neratinib, its core revenue source, and Pfizer's (PFE) life cycle management strategy for its CDK4/6 pipeline.
Source: ClinicalTrials.gov (api_ct)